Business Information
The group's principal activity is to develop, manufacture and market pharmaceutical products for unmet medical needs in both niche and larger market segments. The group distributes its products on a worldwide basis primarily through a direct sales force in the United States, the United Kingdom and Israel. . The group's major products are oxandrin (R), bio-tropin tm, delatestryl (R), biolon (R), mircette (R), silkis(R) and bio-hep-b (r). The group maintaining worldwide approximately 409 issued patents either owned or exclusively licensed including 63 patents issued in the United States, 16 patents issued by the European patent office, which in turn resulted in the issuance of 160 national patents in Europe, and 17 patents issued in Israel.
|
|
Name |
Title
|
Email
|
| Stephen Jaeger | Chmn. | N/A | | Brian Hayden | Sr. VP, CFO, Treasurer | N/A | | Paul Hamelin | Sr. VP - Commercial Operations | N/A | | Philip Yachmetz | Exec. VP, Chief Business Officer | N/A | | Robert Lamm | Sr. VP - Quality, Regulatory Affairs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 47,514 | 60,325 | | 2005 | 87,794 | 5,968 | | 2004 | 123,895 | (27,515)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
